Liège, Belgium - April 27th 2026
White Raven, a Belgian CDMO specialized in GMP aseptic fill-finish for injectable drug products, has entered into a partnership with Orpha Trade GmbH to support drug product manufacturing for a Phase I clinical program.
Under the agreement, White Raven will perform aseptic fill-finish activities at its facility in Liège, Belgium. The collaboration brings together Orpha Trade’s program leadership and White Raven’s expertise in flexible, small-batch GMP manufacturing for early clinical development.
The partnership reflects a shared focus on quality, execution, and close technical collaboration at a stage where speed and manufacturing reliability are critical to program progress.
This partnership marks an important step for our Phase I program. We were looking for a manufacturing partner with the right combination of technical capability, flexibility, and responsiveness. White Raven offers an approach that fits the needs of an early-stage program, and we are pleased to be working together.”
No further details regarding the program are being disclosed at this time.
We are proud to support Orpha Trade in this Phase I program.
Early clinical manufacturing requires agility, technical rigor, and clear communication at every step. That is exactly how we work at White Raven.
Our team is built to support innovative drug developers with a flexible and reliable aseptic fill-finish model adapted to small batches and accelerated timelines.”
About White Raven
White Raven is a Belgium-based CDMO specialized in GMP formulation and aseptic fill-finish of injectable drug products for small batches. Built for clinical-stage manufacturing, White Raven combines gloveless robotic isolator technology, a fully single-use setup, and digitalized operations to reduce risk, shorten timelines, and simplify execution for biotech partners.
From its facility in Liège, White Raven supports customers developing innovative therapies with a manufacturing model designed for flexibility, high sterility assurance, and batch release in less than four months from project start.
Website: https://whiteraven.bio
About Orpha Trade GmbH
Orpha Trade GmbH is a Vienna-based pharmaceutical company focused on licensing, lifecycle management, and strategic development of medicinal products across several therapeutic areas.
The project portfolio includes innovative new compounds in comprehensive preclinical research and gearing up for first-in-human trials, as well as generics development and optimization of well-established compounds.
Media Contacts
White Raven
Adam Soufi - Marketing Director
Email: adam@whiteraven.bio
Orpha Trade
Claudia Turetschek - Director R&D and BD
Email: office@orphatrade.com